Understanding reading comprehension : multiple and focused strategy interventions for struggling adolescent readers

The purpose of this study was to investigate methods for improving reading comprehension among struggling adolescent readers. More specifically, this study was concerned with: the effectiveness of pull-out intervention for reading outcomes in this population; the most effective type of intervention; and the contributions of instructional method to reading comprehension after decoding has been removed. These questions were answered with the help of 29 students from a rural school division in Saskatchewan who volunteered to participate in testing and various forms of reading intervention for a period of four to five weeks. Students were placed into one of three groups: the MSI group practiced decoding and learned six comprehension strategies; the FSI group practiced decoding and learned just two comprehension strategies; and the control group who participated in their typical education program. In sum, the analysis produced the following results: 1.Pull-out intervention (pre-test M = 6.00; post-test M = 7.33) did not offer a statistically significant advantage over the typical classroom setting (pre-test M = 7.00; post-test M = 7.05) when attempting to remediate reading comprehension; 2.Participants in the MSI group demonstrated significant improvement on measures of decoding (p = .001; ©¯p2 = .75); 3.Although statistical testing did not reveal significant results, effect sizes were large for: participants in the MSI group on measures of fluency (©¯p2 = .39); participants in the FSI group on measures of fluency (©¯p2 = .53) and the Oral Reading Quotient (©¯p2 = .37); participants in the control group on measures of decoding (©¯p2 = .21), comprehension (©¯p2 = .38), fluency (©¯p2 = .32), and the Oral Reading Quotient (©¯p2 = .50); and 4.Decoding accounted for a statistically significant 15.4% of the unique variance in post-test comprehension scores (p = .03), but differences in grouping contributed a negligible amount (p = .1; R2 change = .004)

« Pieds Flous et la moufette » : les théories d’apprentissage occidentales et autochtones racontées

This article looks at how Indigenous and Western perspectives on learning and development are interwoven and come into dialogue with one another to create supportive and inclusive classrooms for Indigenous (and all) students. We use a storytelling methodology to address this focus and offer a holistic approach to our analysis. Specifically, we provide a fictional story followed by an in-depth analysis to tease out how Indigenous students continue to experience racism and colonialism in schools and what theories of learning and development may offer in addressing these challenges. This article offers insight about how both practising teachers and teacher educators can build upon the wisdom of Indigenous ways of learning and Western educational practices to re-imagine inclusive classrooms that can support Indigenous (and all) learners.Cet article réfléchit à la manière dont les perspectives autochtones et occidentales concernant le développement peuvent s’entremêler et entrer en dialogue pour créer des classes solidaires et inclusives pour les élèves autochtones (et tous). Nous utilisons une méthodologie narrative pour répondre à cet objectif et proposer une approche holistique à notre analyse. Plus précisément, nous partageons une histoire fictive suivie d'une analyse approfondie pour découvrir comment les élèves autochtones continuent d'être confrontés au racisme et au colonialisme dans les écoles, puis nous examinons ce que les théories de l'apprentissage et du développement peuvent offrir pour relever ces défis. Cet article offre un aperçu de la manière dont les enseignants et les formateurs d’enseignants peuvent s’appuyer sur la sagesse des méthodes d’apprentissage autochtones et des pratiques éducatives occidentales pour réinventer des classes inclusives qui peuvent soutenir les apprenants autochtones (et tous)

Cancer Biomarkers and Targets in Digestive Organs

Identification and development of cancer biomarkers and targets have greatly accelerated progress towards precision medicine in oncology. Studies of tumor biology have not only provided insights into the mechanisms underlying carcinogenesis, but also led to discovery of molecules that have been developed into cancer biomarkers and targets. Multi-platforms for molecular characterization of tumors using next-generation genomic sequencing, immunohistochemistry, in situ hybridization, and blood-based biopsies have greatly expanded the portfolio of potential biomarkers and targets. These cancer biomarkers have been developed for diagnosis, early detection, prognosis, and prediction of treatment response. The molecular targets have been exploited for anti-cancer therapy and delivery of therapeutic agents. This Special Issue of Biomedicines focuses on recent advances in the discovery, characterization, translation, and clinical application of cancer biomarkers and targets in malignant diseases of the digestive system. The goal is to stimulate basic and translational research and clinical collaboration in this exciting field with the hope of developing strategies for prevention and early detection/diagnosis of cancer in digestive organs, and improving therapeutic and psychosocial outcomes in patients with these malignant diseases

Decolonizing Possibilities in Special Education Services

Colonial contexts continue to shape the experiences of Indigenous students, especially in special education, even as educators work to respond to Indigenous perspectives. In this article we first apply a decolonizing critique to consider how colonialism affects special education programming, then survey Indigenous and decolonizing scholarship to (re)imagine how educators may start to address these concerns. Our analysis suggests that educators (1) engage in critical self-examination, (2) adopt holistic assessment strategies, (3) explore teaching practices emerging from decolonizing perspectives, and (4) examine and (re)imagine service delivery models. Educators may use these ideas as a springboard for exploring more contextualized decolonizing possibilities. Keywords: inclusive education, special education, decolonizationLes contextes coloniaux continuent de façonner les expériences des élèves autochtones, en particulier en enseignement spécialisé, et ce, même si les éducateurs s’efforcent de s’adapter au point de vue autochtone. Dans cet article, nous utilisons une critique de la décolonisation afin d’examiner comment le colonialisme affecte les programmes d’éducation spécialisée, et nous sondons le savoir autochtone et de décolonisation pour (ré)imaginer par où les éducateurs peuvent commencer pour répondre à ces préoccupations. Notre analyse permet de suggérer aux éducateurs de : (1) s’engager dans un autoexamen critique, (2) d’adopter des stratégies d’évaluation holistiques, (3) d’explorer les pratiques d’enseignement émergeant des perspectives de décolonisation, et (4) d’examiner et de (ré)imaginer des modèles de prestation de services. Les éducateurs peuvent utiliser ces idées comme un tremplin pour explorer des pistes de décolonisation plus contextualisées. Mots-clés : éducation inclusive, éducation spécialisée, décolonisatio

Understanding Reading: A Model of Meaningful Reading

A theory of reading provides the foundation for reading research, instruction and remediation. The Simple View of Reading (SVR) forms the basis of many present day understandings of reading. However, this and other current reading theories seem to be missing significant components that can contribute to a more holistic understanding of the reading process and subsequent models of reading. An incomplete understanding of the reading process can hinder efforts at targeted interventions and the full development of student abilities. This article serves to consolidate several ideas about reading to create a comprehensive, and thus more useful, Model of Meaningful Reading

Emerging Targeted Therapies for Treatment of Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) has dismal diagnosis due to the presence of underlying cirrhosis, late diagnosis, and limited treatment options. Surgery or liver transplantation is restricted to those with small tumours or well-compensated liver diseases. Despite advances in early screening and diagnosis of HCC, survival of patients has not improved greatly. Furthermore, treatment options for advanced HCC are restricted to best supportive care. Currently, sorafenib is the only drug approved for the treatment of advanced HCC patients as well as for those not suitable for transarterial chemoembolization (TACE). Therefore, there is an urgent need to develop new agents for treatment. Hepatocarcinogenesis is a complex multistep process that involves deregulation of various signalling pathways. Thus, there is no dominant molecular mechanism in HCC and understanding of these pathways provides an opportunity for development of potential therapeutic agents in an effort to reverse, prevent or delay tumourigenesis. This review will summarise the significance of these pathways in HCC and discuss the therapeutic benefits or drawbacks of the potential target agents against these pathways especially those that have been part of clinical trials

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation